PE20200718A1 - Compuestos - Google Patents
CompuestosInfo
- Publication number
- PE20200718A1 PE20200718A1 PE2019002464A PE2019002464A PE20200718A1 PE 20200718 A1 PE20200718 A1 PE 20200718A1 PE 2019002464 A PE2019002464 A PE 2019002464A PE 2019002464 A PE2019002464 A PE 2019002464A PE 20200718 A1 PE20200718 A1 PE 20200718A1
- Authority
- PE
- Peru
- Prior art keywords
- heteroaryl
- group
- independently selected
- alkoxy
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Referida a un compuesto de formula (l), donde A es arilo o heteroarilo; B es arilo o heteroarilo; C es heteroarilo; R1 se selecciona, independientemente, del grupo que consiste en amino, C1-6-alquilo, C1-6-alcoxi, entre otros; R2 se selecciona, independientemente, del grupo que consiste en -(CH2)k-N(R4,R5), -(C=O)-N(R4,R5), halogeno, entre otros; R3 se selecciona, independientemente, del grupo que consiste en amino, C1-6-alquilo, C1-6-alcoxi, entre otros; k es 0,1 o 2; n es 0, 1, 2 o 3; m es 0, 1 o 2; p es 0 o 1. Dichos compuestos son inhibidores alostericos selectivos de mutantes de receptor del factor de crecimiento epidermico (EGFR), siendo utiles en el tratamiento de cancer. Tambien se refiere a composiciones farmaceuticas que contienen dicho compuesto y su utilizacion como sustancias terapeuticamente activas.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762514244P | 2017-06-02 | 2017-06-02 | |
| EP17174334 | 2017-06-02 | ||
| US201762543438P | 2017-08-10 | 2017-08-10 | |
| PCT/EP2018/064399 WO2018220149A1 (en) | 2017-06-02 | 2018-06-01 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200718A1 true PE20200718A1 (es) | 2020-07-21 |
Family
ID=62495802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019002464A PE20200718A1 (es) | 2017-06-02 | 2018-06-01 | Compuestos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11117890B2 (es) |
| EP (1) | EP3630754B8 (es) |
| JP (1) | JP7191045B2 (es) |
| KR (1) | KR20200015595A (es) |
| CN (1) | CN110753691B (es) |
| AU (1) | AU2018276441B2 (es) |
| BR (1) | BR112019025370A2 (es) |
| CA (1) | CA3065874A1 (es) |
| CL (1) | CL2019003501A1 (es) |
| CO (1) | CO2019013557A2 (es) |
| CR (1) | CR20190542A (es) |
| ES (1) | ES2927480T3 (es) |
| IL (1) | IL271013B2 (es) |
| MA (1) | MA48946A (es) |
| MX (1) | MX2019014332A (es) |
| MY (1) | MY201976A (es) |
| PE (1) | PE20200718A1 (es) |
| PH (1) | PH12019502662A1 (es) |
| PL (1) | PL3630754T3 (es) |
| TW (1) | TWI774780B (es) |
| UA (1) | UA126452C2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023116779A1 (zh) * | 2021-12-21 | 2023-06-29 | 上海艾力斯医药科技股份有限公司 | 一种联炔类化合物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007143434A2 (en) | 2006-05-31 | 2007-12-13 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents |
| JP2010530736A (ja) * | 2007-05-25 | 2010-09-16 | バーンハム インスティトゥート フォー メディカル リサーチ | タプシガルジンにより誘導される細胞死の阻害剤 |
| EP2307365B1 (en) * | 2008-06-25 | 2013-03-27 | Merck Sharp & Dohme Corp. | Synthesis and use of heterocyclic antibacterial agents |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| CN102060848B (zh) | 2010-12-09 | 2013-09-18 | 天津药物研究院 | 芳香胺取代的嘧啶衍生物的制备及用途 |
| CN102093339B (zh) | 2010-12-09 | 2013-06-12 | 天津药物研究院 | 一类嘧啶衍生物的制备及用途 |
| WO2013170770A1 (zh) * | 2012-05-16 | 2013-11-21 | 上海医药集团股份有限公司 | 具有抗肿瘤活性的乙炔衍生物 |
| CN106687446B (zh) * | 2014-07-18 | 2020-04-28 | 百济神州(北京)生物科技有限公司 | 作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途 |
| DK3205650T3 (da) * | 2014-10-11 | 2021-09-13 | Shanghai Hansoh Biomedical Co Ltd | Egfr-hæmmer og fremstilling og anvendelse deraf |
| CN113149885A (zh) * | 2015-05-14 | 2021-07-23 | 威斯塔解剖学和生物学研究所 | Ebna1抑制剂和使用其的方法 |
| CN107849034B (zh) * | 2015-06-30 | 2021-09-03 | 达纳－法伯癌症研究所公司 | Egfr抑制剂及其使用方法 |
| TW201834651A (zh) * | 2016-12-22 | 2018-10-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
-
2018
- 2018-06-01 UA UAA202000003A patent/UA126452C2/uk unknown
- 2018-06-01 PE PE2019002464A patent/PE20200718A1/es unknown
- 2018-06-01 CR CR20190542A patent/CR20190542A/es unknown
- 2018-06-01 AU AU2018276441A patent/AU2018276441B2/en active Active
- 2018-06-01 ES ES18728875T patent/ES2927480T3/es active Active
- 2018-06-01 BR BR112019025370-0A patent/BR112019025370A2/pt unknown
- 2018-06-01 TW TW107118846A patent/TWI774780B/zh active
- 2018-06-01 MA MA048946A patent/MA48946A/fr unknown
- 2018-06-01 MX MX2019014332A patent/MX2019014332A/es unknown
- 2018-06-01 JP JP2019566634A patent/JP7191045B2/ja active Active
- 2018-06-01 EP EP18728875.8A patent/EP3630754B8/en active Active
- 2018-06-01 PL PL18728875.8T patent/PL3630754T3/pl unknown
- 2018-06-01 CA CA3065874A patent/CA3065874A1/en active Pending
- 2018-06-01 CN CN201880036589.7A patent/CN110753691B/zh active Active
- 2018-06-01 MY MYPI2019007060A patent/MY201976A/en unknown
- 2018-06-01 KR KR1020197038496A patent/KR20200015595A/ko not_active Application Discontinuation
-
2019
- 2019-11-25 PH PH12019502662A patent/PH12019502662A1/en unknown
- 2019-11-28 IL IL271013A patent/IL271013B2/en unknown
- 2019-11-29 CO CONC2019/0013557A patent/CO2019013557A2/es unknown
- 2019-11-29 CL CL2019003501A patent/CL2019003501A1/es unknown
- 2019-12-02 US US16/700,900 patent/US11117890B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI774780B (zh) | 2022-08-21 |
| UA126452C2 (uk) | 2022-10-05 |
| AU2018276441B2 (en) | 2022-04-28 |
| CO2019013557A2 (es) | 2020-01-17 |
| IL271013B2 (en) | 2023-02-01 |
| MY201976A (en) | 2024-03-27 |
| IL271013B (en) | 2022-10-01 |
| CN110753691B (zh) | 2024-02-02 |
| CL2019003501A1 (es) | 2020-06-05 |
| JP7191045B2 (ja) | 2022-12-16 |
| RU2019143647A (ru) | 2021-07-09 |
| US20200102299A1 (en) | 2020-04-02 |
| RU2019143647A3 (es) | 2021-09-28 |
| MX2019014332A (es) | 2022-03-24 |
| ES2927480T3 (es) | 2022-11-07 |
| EP3630754B1 (en) | 2022-07-27 |
| PH12019502662A1 (en) | 2020-06-08 |
| IL271013A (en) | 2020-01-30 |
| CN110753691A (zh) | 2020-02-04 |
| BR112019025370A2 (pt) | 2020-06-23 |
| CA3065874A1 (en) | 2018-12-06 |
| US11117890B2 (en) | 2021-09-14 |
| AU2018276441A1 (en) | 2019-12-12 |
| KR20200015595A (ko) | 2020-02-12 |
| PL3630754T3 (pl) | 2022-10-24 |
| EP3630754A1 (en) | 2020-04-08 |
| JP2020524659A (ja) | 2020-08-20 |
| EP3630754B8 (en) | 2022-08-31 |
| MA48946A (fr) | 2020-04-08 |
| TW201902892A (zh) | 2019-01-16 |
| CR20190542A (es) | 2020-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092896A1 (ru) | Гетероциклические и гетероарильные соединения для лечения болезни гентингтона | |
| PE20200292A1 (es) | Compuestos de heteroarilo biciclicos 6-6 fusionados y su uso como inhibidores de lats | |
| PE20191541A1 (es) | Composiciones y metodos para inhibir la accion de la arginasa | |
| CY1121694T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| EA201991399A1 (ru) | Аминотриазолопиридиновые соединения и их применение в лечении рака | |
| EA201891203A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| BR112018012756A2 (pt) | compostos heterocíclicos como imunomoduladores | |
| EA201992878A1 (ru) | Соединения для лечения болезни хантингтона | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
| CL2016002033A1 (es) | Compuestos derivados de benzimidazol-2 amino con actividad inhibidora (midh1 r132h); composición farmacéutica, procedimiento de preparación; uso en el tratamiento de tumores gastrointestinales, tumor endocrino, síndrome mielodisplásico, leucemia, tumor de mamas, , metástasis, entre otros. | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| PE20170662A1 (es) | Compuestos de aminopiridiloxipirazol | |
| PE20181345A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer | |
| PE20161384A1 (es) | Ciclopropilaminas como inhibidores de lsd 1 | |
| CY1120325T1 (el) | Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης | |
| PE20160689A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
| BR112016029846A2 (pt) | ?composto, composição farmacêutica, métodos para o método para tratamento de um humano, para inibição da atividade de um polipeptídio de fosfatidilinositol 3-quinase e inibição excessiva ou reações imunes destrutivas ou crescimento ou uma proliferação de células de câncer, kit, e, uso de um composto, um sal farmaceuticamente aceitável, isômero, ou uma mistura do mesmo? | |
| EA201892745A1 (ru) | Фосфорамидатные производные нуклеозида в качестве противораковых агентов | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| EA201991580A1 (ru) | Пиримидиновое соединение и его фармацевтическое применение | |
| PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| EA201792374A1 (ru) | Азабензимидазолы и их применение в качестве модуляторов рецептора ampa |